Paradigm Capital Management Inc. NY lessened its stake in Mednax, Inc (NYSE:MD) by 26.4% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 57,575 shares of the company’s stock after selling 20,700 shares during the period. Paradigm Capital Management Inc. NY owned about 0.06% of Mednax worth $2,483,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in Mednax by 0.3% in the 2nd quarter. BlackRock Inc. now owns 8,257,495 shares of the company’s stock valued at $498,505,000 after purchasing an additional 28,155 shares during the last quarter. Vanguard Group Inc. increased its holdings in Mednax by 0.5% in the 2nd quarter. Vanguard Group Inc. now owns 7,551,130 shares of the company’s stock valued at $455,862,000 after purchasing an additional 38,645 shares during the last quarter. Longview Partners Guernsey LTD increased its holdings in Mednax by 10.3% in the 2nd quarter. Longview Partners Guernsey LTD now owns 5,023,476 shares of the company’s stock valued at $303,267,000 after purchasing an additional 467,845 shares during the last quarter. Victory Capital Management Inc. increased its holdings in Mednax by 22.6% in the 2nd quarter. Victory Capital Management Inc. now owns 2,423,865 shares of the company’s stock valued at $146,329,000 after purchasing an additional 446,074 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC increased its holdings in Mednax by 95.9% in the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 2,170,741 shares of the company’s stock valued at $131,048,000 after purchasing an additional 1,062,584 shares during the last quarter. Hedge funds and other institutional investors own 96.28% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Paradigm Capital Management Inc. NY Reduces Position in Mednax, Inc (MD)” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/paradigm-capital-management-inc-ny-reduces-position-in-mednax-inc-md/1700169.html.

Shares of Mednax, Inc (MD) traded down C$0.18 during mid-day trading on Monday, reaching C$44.47. 1,652,900 shares of the company’s stock traded hands, compared to its average volume of 1,005,275. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.37. Mednax, Inc has a 52 week low of C$40.56 and a 52 week high of C$72.13. The stock has a market cap of $4,160.00, a PE ratio of 13.60, a PEG ratio of 1.43 and a beta of 0.32.

Mednax (NYSE:MD) last issued its quarterly earnings results on Wednesday, November 1st. The company reported C$0.87 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of C$0.87. The company had revenue of C$868.95 million during the quarter, compared to analysts’ expectations of C$864.78 million. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The firm’s revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the company posted $1.09 EPS. sell-side analysts predict that Mednax, Inc will post 3.1 earnings per share for the current fiscal year.

MD has been the subject of several research reports. BidaskClub downgraded shares of Mednax from a “sell” rating to a “strong sell” rating in a report on Friday, August 4th. Robert W. Baird reiterated a “hold” rating and issued a $47.00 target price on shares of Mednax in a report on Sunday, September 3rd. Zacks Investment Research upgraded shares of Mednax from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Jefferies Group LLC set a $46.00 target price on shares of Mednax and gave the company a “hold” rating in a report on Sunday, July 30th. Finally, KeyCorp set a $51.00 target price on shares of Mednax and gave the company a “buy” rating in a report on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the stock. Mednax presently has an average rating of “Hold” and an average price target of C$54.50.

In other news, Director Cesar L. Alvarez sold 10,668 shares of Mednax stock in a transaction on Friday, November 3rd. The shares were sold at an average price of C$42.59, for a total transaction of C$454,350.12. Following the completion of the sale, the director now directly owns 44,215 shares of the company’s stock, valued at approximately C$1,883,116.85. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider John C. Pepia sold 3,000 shares of Mednax stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of C$42.85, for a total transaction of C$128,550.00. Following the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at C$1,524,131.65. The disclosure for this sale can be found here. 2.40% of the stock is currently owned by insiders.

Mednax Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.